PC
CARM

Polar Capital’s Carisma Therapeutics CARM Stock Holding History

Polar Capital’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,402
Closed -$250K – 291
2015
Q1 		$250K Buy
+1,402
New +$306K ﹤0.01% 281

Other funds holding CARM

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Polar Capital's CARM Position: Q2 2015 in Review

Polar Capital sold out of Carisma Therapeutics (CARM) in Q2 2015, closing a stake of 1,402 shares — an estimated $250K sold.

Polar Capital first reported a position in CARM in Q1 2015 and held it in 1 quarter. The position peaked at $250K in Q1 2015. 41 funds tracked by Wall St. Rank hold CARM as of Q2 2015.

  • Polar Capital reported no remaining Carisma Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Polar Capital sold 1,402 Carisma Therapeutics shares in Q2 2015, an estimated $250K.
  • Polar Capital first reported a position in Carisma Therapeutics in Q1 2015 and held it in 1 quarter.
  • Polar Capital's Carisma Therapeutics position peaked at $250K in Q1 2015.
  • 41 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2015.

Based on Polar Capital's 13F filing for Q2 2015, filed 14 Aug 2015.